EMBECTA CORP. Accounts Receivable
EMBECTA CORP. (EMBC) had Accounts Receivable of $182.20 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-07
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $182.20M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $147.10M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $159.20M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $145.60M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $182.20M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $147.10M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $159.20M 10-Q · filed 2026-02-05 |
| 2025-09-30 | $145.60M 10-Q · filed 2026-08-07 |
| 2025-06-30 | $182.80M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $185.60M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $180.90M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $193.00M 10-K · filed 2025-11-25 |
| 2024-06-30 | $171.80M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $123.70M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $96.10M 10-Q · filed 2024-02-09 |
| 2023-09-30 | $16.70M 10-K · filed 2024-12-11 |
| 2023-06-30 | $21.10M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $19.10M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $19.90M 10-Q · filed 2023-02-14 |
| 2022-09-30 | $22.20M 10-K · filed 2023-11-29 |
| 2022-06-30 | $22.20M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $15.20M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $118.30M 10-Q · filed 2022-03-16 |
| 2021-09-30 | $150.60M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |